First Time Loading...

Curis Inc
NASDAQ:CRIS

Watchlist Manager
Curis Inc Logo
Curis Inc
NASDAQ:CRIS
Watchlist
Price: 15.22 USD -4.58%
Updated: Apr 19, 2024

Intrinsic Value

CRIS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. [ Read More ]

The intrinsic value of one CRIS stock under the Base Case scenario is 9.33 USD. Compared to the current market price of 15.22 USD, Curis Inc is Overvalued by 39%.

Key Points:
CRIS Intrinsic Value
Base Case
9.33 USD
Overvaluation 39%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Curis Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CRIS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Curis Inc

Provide an overview of the primary business activities
of Curis Inc.

What unique competitive advantages
does Curis Inc hold over its rivals?

What risks and challenges
does Curis Inc face in the near future?

Has there been any significant insider trading activity
in Curis Inc recently?

Summarize the latest earnings call
of Curis Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Curis Inc.

Provide P/S
for Curis Inc.

Provide P/E
for Curis Inc.

Provide P/OCF
for Curis Inc.

Provide P/FCFE
for Curis Inc.

Provide P/B
for Curis Inc.

Provide EV/S
for Curis Inc.

Provide EV/GP
for Curis Inc.

Provide EV/EBITDA
for Curis Inc.

Provide EV/EBIT
for Curis Inc.

Provide EV/OCF
for Curis Inc.

Provide EV/FCFF
for Curis Inc.

Provide EV/IC
for Curis Inc.

Show me price targets
for Curis Inc made by professional analysts.

What are the Revenue projections
for Curis Inc?

How accurate were the past Revenue estimates
for Curis Inc?

What are the Net Income projections
for Curis Inc?

How accurate were the past Net Income estimates
for Curis Inc?

What are the EPS projections
for Curis Inc?

How accurate were the past EPS estimates
for Curis Inc?

What are the EBIT projections
for Curis Inc?

How accurate were the past EBIT estimates
for Curis Inc?

Compare the revenue forecasts
for Curis Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Curis Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Curis Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Curis Inc compared to its peers.

Compare the P/E ratios
of Curis Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Curis Inc with its peers.

Analyze the financial leverage
of Curis Inc compared to its main competitors.

Show all profitability ratios
for Curis Inc.

Provide ROE
for Curis Inc.

Provide ROA
for Curis Inc.

Provide ROIC
for Curis Inc.

Provide ROCE
for Curis Inc.

Provide Gross Margin
for Curis Inc.

Provide Operating Margin
for Curis Inc.

Provide Net Margin
for Curis Inc.

Provide FCF Margin
for Curis Inc.

Show all solvency ratios
for Curis Inc.

Provide D/E Ratio
for Curis Inc.

Provide D/A Ratio
for Curis Inc.

Provide Interest Coverage Ratio
for Curis Inc.

Provide Altman Z-Score Ratio
for Curis Inc.

Provide Quick Ratio
for Curis Inc.

Provide Current Ratio
for Curis Inc.

Provide Cash Ratio
for Curis Inc.

What is the historical Revenue growth
over the last 5 years for Curis Inc?

What is the historical Net Income growth
over the last 5 years for Curis Inc?

What is the current Free Cash Flow
of Curis Inc?

Financials

Balance Sheet Decomposition
Curis Inc

Current Assets 60.9m
Cash & Short-Term Investments 56.3m
Receivables 2.8m
Other Current Assets 1.8m
Non-Current Assets 16.4m
PP&E 3.5m
Intangibles 9m
Other Non-Current Assets 3.9m
Current Liabilities 13.5m
Accounts Payable 3.2m
Accrued Liabilities 10.3m
Non-Current Liabilities 44.1m
Other Non-Current Liabilities 44.1m
Efficiency

Earnings Waterfall
Curis Inc

Revenue
10m USD
Cost of Revenue
-212k USD
Gross Profit
9.8m USD
Operating Expenses
-58.1m USD
Operating Income
-48.3m USD
Other Expenses
919k USD
Net Income
-47.4m USD

Free Cash Flow Analysis
Curis Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

CRIS Profitability Score
Profitability Due Diligence

Curis Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Negative 1-Year Revenue Growth
Negative 3-Years Revenue Growth
20/100
Profitability
Score

Curis Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

CRIS Solvency Score
Solvency Due Diligence

Curis Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
43/100
Solvency
Score

Curis Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CRIS Price Targets Summary
Curis Inc

Wall Street analysts forecast CRIS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CRIS is 22.19 USD with a low forecast of 15.15 USD and a high forecast of 27.3 USD.

Lowest
Price Target
15.15 USD
0% Downside
Average
Price Target
22.19 USD
46% Upside
Highest
Price Target
27.3 USD
79% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CRIS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CRIS Price
Curis Inc

1M 1M
+49%
6M 6M
+229%
1Y 1Y
-15%
3Y 3Y
-93%
5Y 5Y
-57%
10Y 10Y
-94%
Annual Price Range
15.22
52w Low
0.38
52w High
18.68
Price Metrics
Average Annual Return 65.66%
Standard Deviation of Annual Returns 218.35%
Max Drawdown -100%
Shares Statistics
Market Capitalization 89.7m USD
Shares Outstanding 5 894 080
Percentage of Shares Shorted 0.85%

CRIS Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Curis Inc Logo
Curis Inc

Country

United States of America

Industry

Biotechnology

Market Cap

89.7m USD

Dividend Yield

0%

Description

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of therapeutics for the treatment of cancer. Its clinical stage drug candidates are Emavusertib and CI-8993. Emavusertib is an orally available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (VISTA). Its pipeline also includes Fimepinostat, CA-170 and CA-327. Fimepinostat is a small molecule that inhibits the activity of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3) enzymes. CA-170 is a small molecule antagonist of VISTA and PDL1. CA-327 is a small molecule antagonist of PDL1 and TIM3, which is a pre-IND stage oncology drug candidate.

Contact

MASSACHUSETTS
Lexington
128 Spring Street, Building C, Suite 500
+16175036500.0
http://www.curis.com/

IPO

2000-08-01

Employees

60

Officers

President, CEO, Secretary, Treasurer & Director
Mr. James E. Dentzer
CFO and Principal Financial & Accounting Officer
Ms. Diantha Duvall CPA, M.B.A.
Vice President of Technology Management & Intellectual Property
Mr. Mark W. Noel
VP of Investor Relations & Corporate Communications
Ms. Elif McDonald
Senior Vice President of Clinical Development
Dr. Reinhard Wilhelm von Roemeling M.D.
Chief Development Officer
Dr. Jonathan B. Zung Ph.D.

See Also

Discover More
What is the Intrinsic Value of one CRIS stock?

The intrinsic value of one CRIS stock under the Base Case scenario is 9.33 USD.

Is CRIS stock undervalued or overvalued?

Compared to the current market price of 15.22 USD, Curis Inc is Overvalued by 39%.